SI1755674T1 - Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa - Google Patents

Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa

Info

Publication number
SI1755674T1
SI1755674T1 SI200531936T SI200531936T SI1755674T1 SI 1755674 T1 SI1755674 T1 SI 1755674T1 SI 200531936 T SI200531936 T SI 200531936T SI 200531936 T SI200531936 T SI 200531936T SI 1755674 T1 SI1755674 T1 SI 1755674T1
Authority
SI
Slovenia
Prior art keywords
allograft
prolongation
survival
complement activity
inhibiting complement
Prior art date
Application number
SI200531936T
Other languages
English (en)
Slovenian (sl)
Inventor
Russell P. Rother
Hao Wang
Zhen Zhong
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1755674(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of SI1755674T1 publication Critical patent/SI1755674T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200531936T 2004-05-14 2005-05-16 Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa SI1755674T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57144404P 2004-05-14 2004-05-14
PCT/US2005/017048 WO2005110481A2 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity
EP05779924.9A EP1755674B1 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Publications (1)

Publication Number Publication Date
SI1755674T1 true SI1755674T1 (sl) 2015-04-30

Family

ID=35385551

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531936T SI1755674T1 (sl) 2004-05-14 2005-05-16 Podaljšanje preživetja alotransplantata z inhibiranjem aktivnosti komplementa

Country Status (14)

Country Link
US (3) US20090028850A1 (cg-RX-API-DMAC7.html)
EP (4) EP2338511A3 (cg-RX-API-DMAC7.html)
JP (3) JP5161567B2 (cg-RX-API-DMAC7.html)
AU (1) AU2005244012C1 (cg-RX-API-DMAC7.html)
CA (1) CA2566716C (cg-RX-API-DMAC7.html)
DK (1) DK1755674T3 (cg-RX-API-DMAC7.html)
ES (1) ES2528362T3 (cg-RX-API-DMAC7.html)
HK (2) HK1222342A1 (cg-RX-API-DMAC7.html)
IL (2) IL179240A (cg-RX-API-DMAC7.html)
NZ (1) NZ551308A (cg-RX-API-DMAC7.html)
PL (1) PL1755674T3 (cg-RX-API-DMAC7.html)
PT (1) PT1755674E (cg-RX-API-DMAC7.html)
SI (1) SI1755674T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005110481A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体関連障害を処置するための方法および組成物
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
JP5871798B2 (ja) * 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011146395A2 (en) * 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
EP3033093A1 (en) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP6479974B2 (ja) * 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ, インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
US20180311299A1 (en) * 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
CN120344253A (zh) * 2022-12-08 2025-07-18 诺麦塔制药有限公司 延长移植物和受体存活期的组合物和方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
CA2097825A1 (en) * 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
IL137614A0 (en) 1998-02-04 2001-07-24 Gen Hospital Corp An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
ATE449791T1 (de) * 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
WO2005025509A2 (en) * 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
MXPA06013463A (es) * 2004-05-17 2007-03-01 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios.

Also Published As

Publication number Publication date
JP5161567B2 (ja) 2013-03-13
PL1755674T3 (pl) 2015-05-29
EP3056218A1 (en) 2016-08-17
IL233326A0 (en) 2014-08-31
ES2528362T3 (es) 2015-02-09
HK1201758A1 (en) 2015-09-11
EP2338511A2 (en) 2011-06-29
WO2005110481A3 (en) 2006-06-22
DK1755674T3 (en) 2015-02-09
IL179240A (en) 2014-07-31
HK1222342A1 (en) 2017-06-30
AU2005244012B2 (en) 2011-08-18
US20090028850A1 (en) 2009-01-29
AU2005244012C1 (en) 2013-05-02
AU2005244012A1 (en) 2005-11-24
IL179240A0 (en) 2007-03-08
EP1755674B1 (en) 2014-11-19
JP2007537299A (ja) 2007-12-20
WO2005110481A2 (en) 2005-11-24
US20190309053A1 (en) 2019-10-10
AU2005244012B9 (en) 2011-11-03
NZ551308A (en) 2009-06-26
JP2013032391A (ja) 2013-02-14
JP5590624B2 (ja) 2014-09-17
CA2566716C (en) 2014-12-23
EP1755674A2 (en) 2007-02-28
PT1755674E (pt) 2015-02-05
JP2014080438A (ja) 2014-05-08
HK1101962A1 (en) 2007-11-02
EP2338511A3 (en) 2012-07-25
CA2566716A1 (en) 2005-11-24
US20170267751A1 (en) 2017-09-21
EP2815767A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
IL233326A0 (en) Extending the survival of donor tissue by inhibiting the activity of complement
IL193623A0 (en) Prolongation of survival of an allograft by inhibiting complement activity
EP1939198A4 (en) NEW ADENINE COMPOUND
GB2413769B (en) Ureteric stents
AU157196S (en) Watch
IL183510A0 (en) Pyridazinone compounds
IL176942A0 (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
EP1961754A4 (en) BICYCLIC HETEROCYCLIC COMPOUND
AU2011236106B2 (en) Prolongation of survival of an allograft by inhibiting complement activity
ZA200702966B (en) Cryopreservation of cells
IL165618A0 (en) Complementary masks
GB2421064B (en) Improved chamber
GB0520231D0 (en) Improved chamber
TWI317830B (en) Structure of back cover
GB2426775B (en) Chamber riser
PL369353A1 (pl) Zestaw elementów budowlanych
GB0400811D0 (en) Immunosuppressant
GB0422066D0 (en) Improved chamber
GB0412138D0 (en) Definition of zeroclick
ZA200702621B (en) Containment of produce
GB0407251D0 (en) Anti-tangle aid
PL367647A1 (en) Seat-capsule as means of transport
GB0422950D0 (en) Fairing
AU301443S (en) Loading ledge
GB0406115D0 (en) Vox